GAO report on anthrax vaccine production does not instill confidence
The Government Accountability Office released a progress report on the production of a safe effective vaccine against anthrax. We have posted copies of the May 9th report and the highlights on the FAS website.
The report, like their past reports on this issue, cites continued disorganization on the part of the government. Namely, they note that there has been little progress in the area of testing of the current vaccine for safety, effectiveness and reliability. The GAO had previously noted that there has been no long-term safety data, no studies on the optimum number of doses, and inadequate human clinical data. The GAO called upon the Director of Homeland Security to form a strategic plan for the development and safety testing of the vaccine including interagency cooperation.
In 2004, the Department of Health and Human Services awarded a contract for $877.5M for 75 million doses of anthrax vaccine to VaxGen, Inc, a company that had not previously developed and marketed any drugs or vaccines. The contract was noteworthy because it was the first award for bioterrorism countermeasure production under the Project Bioshield.
The GAO noted that the biotech community is watching the anthrax vaccine development and production carefully and warned that if it fails, companies will be less than eager to get involved with government contracts to produce future countermeasures.
The United States Air Force has forward deployed about one-third of its B-2 stealth bombers to Diego Garcia, or about half the B-2s considered fully operational at any given time.
Over the past year, the campaign to abolish nuclear weapons has experienced numerous wins that were celebrated at the Meeting of State Parties.
China is NOT a nuclear “peer” of the United States, as some contend.
China’s total number of approximately 600 warheads constitutes only a small portion of the United States’ estimated stockpile of 3,700 warheads.
Dr. Lim will help develop, organize, and implement FAS’s growing contribution in the area of catastrophic risk including on core areas of nuclear weapons, AI and national security, space, and other emerging technologies.